A vaccine by the company Cansino Biologics has been approved for emergency use as a booster by China’s drug regulator. However, there is no mRNA agent under development, but a nasal spray. The agent uses a viral vector to stimulate the production of components of Sars-CoV-2 in cells. In this way, it is similar to Astrazeneca’s product.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now